Mind Medicine (MindMed) Inc adds new principal investigator and Swiss trial site as it expands Phase 2 study of microdosing LSD for adult ADHD

The Reno-based neuro-pharmaceutical firm’s microdosing division is expanding its slate of research and clinical trials

Mind Medicine (MindMed) Inc (NEO:MMED) () said it had appointed a world-leading psychedelics researcher as principal investigator for the first ever Phase 2a proof-of-concept clinical trial assessing lysergic acid diethylamide (LSD) to treat attention deficit hyperactivity disorder (ADHD) in adults.

It comes as the Reno-based neuro-pharmaceutical firm’s microdosing division, which is assessing consuming very low, sub-hallucinogenic doses of psychedelic ...

Continue Reading →

Investing in Ibogaine Stocks

Two weeks ago, I lost another friend to addiction.

This is the second one this year.

The first was a friend of mine who was a heroin addict and overdosed, after being clean for more than a year.

The second, and most recent, was Nick, who I’ve known for about 20 years. 

We’re still waiting on the toxicology report to find out what happened, but I’m certain prescription opioids were involved, as I know he’s ...

Continue Reading →
Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

NEW YORK, April 16, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  

MindMed is developing 18-MC as a potential treatment for ...

Continue Reading →

Universal Ibogaine Fighting Opioid Dependency with Plant-Based Medicine

Fighting Opioid Dependency with Plant-Based Medicine

This Universal Ibogaine profile is part of a paid investor education campaign.*

Overview

Universal Ibogaine is a Canadian company working to develop compounds to combat the opioid epidemic through plant-based medicine. The company aims to operate and franchise clinics around the world, offering ibogaine as a treatment for opioid-based withdrawals.

Opioids can be found in a number of licit and ...

Continue Reading →
Page 2 of 36 12345...»
UA-77446339-1